Moderna Edges Closer To Becoming A Mid-Stage Drug Development Company

 
• By Jessica Merrill

The mRNA specialist outlined ambitious plans to bring a vaccine for cytomegalovirus to market during an R&D day after releasing positive Phase I data.

micro RNA (let7; pink) bound to mRNA (lin-41; cyan). miRNAs are small non-coding RNA molecules important for gene regulation and implicated in cancer, obesity and heart disease. - Illustration
Moderna is moving forward with mRNA clinical canidates • Source: Shutterstock

More from R&D

More from Scrip